Assuntos
COVID-19 , Progressão da Doença , Humanos , Itália/epidemiologia , Estudos Retrospectivos , Fatores de Risco , SARS-CoV-2RESUMO
BACKGROUND: Chlamydophila pneumoniae and Mycoplasma pneumoniae are associated with acute exacerbation of bronchial asthma (AEBA). The aim of this study was to evaluate the correlation between these acute bacterial infections and the severity of AEBA. METHODS: We prospectively analysed consecutive patients admitted to the Emergency Department with acute asthma exacerbation. In every patient peak expiratory flow (PEF) measurement was performed on admission, and spirometry during follow-up. Serology for Chlamydophila and Mycoplasma pneumoniae was performed on admission and after 4-8 weeks. RESULTS: Fifty-eight patients completed the study. Acute atypical infections (AAI) was observed in 22/58 cases; we found single acute C. pneumoniae in 19 cases, single acute M. pneumoniae in 2 cases, and double acute infection in one case. Functional impairment on admission was greater in patients with AAI than in patients without AAI (PEF 205 +/- 104 L/min vs 276 +/- 117 p = 0.02) and persisted until visit 2 (FEV1% 76.30 +/- 24.54 vs FEV1% 92.91 +/- 13.89, p = 0.002). Moreover, the proportion of patients who presented with severe AEBA was significantly greater in the group with AAI than in the group without AAI (15/22 vs 12/36, p = 0.01; OR 4.29, 95% CI 1.38-13.32). CONCLUSION: Our data suggest an association between acute atypical infection and a more severe AEBA.
Assuntos
Asma/complicações , Infecções por Chlamydophila/complicações , Pneumonia Bacteriana/complicações , Pneumonia por Mycoplasma/complicações , Doença Aguda , Adulto , Infecções por Chlamydophila/diagnóstico , Infecções por Chlamydophila/fisiopatologia , Feminino , Volume Expiratório Forçado/fisiologia , Humanos , Pulmão/microbiologia , Pulmão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Pico do Fluxo Expiratório/fisiologia , Pneumonia Bacteriana/diagnóstico , Pneumonia Bacteriana/fisiopatologia , Pneumonia por Mycoplasma/diagnóstico , Pneumonia por Mycoplasma/fisiopatologia , Prognóstico , Estudos Prospectivos , Índice de Gravidade de Doença , EspirometriaRESUMO
BACKGROUND: Sildenafil is used for pulmonary hypertension treatment and its use is safe in chronic heart failure (HF) patients. AIMS: To analyze the effects of sildenafil on lung mechanics, gas diffusion, exhaled nitric oxide (eNO) at rest and during exercise in chronic HF. We did so to evaluate if sildenafil prevents exercise-induced pulmonary edema formation. METHODS: We studied 22 chronic HF males. We measured after a single dose of placebo, sildenafil (25 mg) and sildenafil (100 mg), lung diffusion (DLCO), molecular diffusion (DM), pulmonary capillary volume (VC), eNO, all at rest and during exercise, standard pulmonary function, and maximal cardiopulmonary exercise. RESULTS: At rest sildenafil improved pulmonary mechanics and DLCO from 23.1+/-6.3 ml/mmHg/min to 23.9+/-6.4 (25 mg, p<0.05) and to 25.3+/-6.7 100 mg, p<0.02). Sildenafil (100 mg) prevents edema formation (highest DM/VC during exercise). At rest eNO was low and not affected by tested drugs. With light exercise eNO was higher with sildenafil 100 mg. Peak VO(2) increased with sildenafil from 1376+/-331 ml/min to 1471+/-375 (25 mg, p<0.01) and 1524+/-461 (100 mg, p<0.02). Peak VO(2) increase was related to DLCO improvement. CONCLUSION: In chronic HF sildenafil increases exercise performance, improves lung mechanics and gas diffusion and prevents exercise-induced pulmonary edema formation probably by restoring NO pathways.
Assuntos
Permeabilidade Capilar/efeitos dos fármacos , Insuficiência Cardíaca/tratamento farmacológico , Piperazinas/uso terapêutico , Alvéolos Pulmonares/irrigação sanguínea , Alvéolos Pulmonares/efeitos dos fármacos , Sulfonas/uso terapêutico , Idoso , Permeabilidade Capilar/fisiologia , Teste de Esforço/efeitos dos fármacos , Teste de Esforço/métodos , Volume Expiratório Forçado/efeitos dos fármacos , Insuficiência Cardíaca/metabolismo , Insuficiência Cardíaca/fisiopatologia , Humanos , Masculino , Ventilação Voluntária Máxima/efeitos dos fármacos , Pessoa de Meia-Idade , Piperazinas/administração & dosagem , Piperazinas/farmacocinética , Alvéolos Pulmonares/fisiopatologia , Capacidade de Difusão Pulmonar/efeitos dos fármacos , Capacidade de Difusão Pulmonar/fisiologia , Purinas/administração & dosagem , Purinas/farmacocinética , Purinas/uso terapêutico , Citrato de Sildenafila , Sulfonas/administração & dosagem , Sulfonas/farmacocinética , Capacidade Vital/efeitos dos fármacosRESUMO
OBJECTIVE: Thrombosis is rare in the young, but can cause severe psychological distress that influences the quality of life and the coping capacities of these patients. This study was meant to increase the understanding of self-perception, social and family functioning and ways of coping with the disease in young patients after an episode of thrombosis. METHODS: Seven questionnaires spanning social and family functioning and ways of coping with disease were completed by 50 patients < or = 45 years of age after a first episode of venous or arterial thrombosis. Data were compared with those of 39 healthy individuals with similar age, sex and level of education. RESULTS: Compared to healthy controls, young patients with thrombosis had lower self-esteem, showed higher impairment in social activities and in familial relationships, and used more frequently coping strategies. Most patients used all coping strategies, preferring the more active ones, but more patients than controls used the passive ones, particularly "avoidance" and "religiosity". A correlation was found between the frequency of use of passive or negative coping strategies and some of the psychological, social and familial dimensions that scored more negatively. Greater psychological impairment and differences in coping styles were found in women compared with men and in individuals < 34 years compared with those > or = 34 years. CONCLUSIONS: Young individuals with thrombosis develop psychological changes that influence their behaviour, quality of life and coping. This is particularly evident in women and in young patients. Physicians dealing with thrombosis should be aware of this situation and offer psychological support.
Assuntos
Trombose/psicologia , Adaptação Psicológica , Adolescente , Adulto , Fatores Etários , Interpretação Estatística de Dados , Educação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Testes Psicológicos , Qualidade de Vida , Fatores de Risco , Autoimagem , Fatores Sexuais , Inquéritos e Questionários , Fatores de TempoRESUMO
BACKGROUND: Few data are available about the long-term outcome of renal transplantation in patients with systemic lupus erythematosus (SLE). METHODS: Between June 1982 and 2004, a total of 33 adults with lupus nephritis received 35 kidney allografts. Outcomes of these grafts and those of 70 controls matched for age, sex, and donor source who underwent transplantation during the same period were compared. RESULTS: Mean follow-up after renal transplantation was 91 +/- 59 months for patients with lupus and 90 +/- 64 months for controls. Actuarial 15-year patient (80% versus 83%) and death-censored graft survival rates (69% versus 67%) were not significantly different between patients with lupus and controls. Risks for acute and chronic rejection, arterial hypertension, and infection were not different between the 2 groups. Mean serum creatinine levels also were similar in the 2 groups at the last follow-up visit. Intravascular thrombotic events occurred in 9 patients with SLE (26%) and 6 controls (8.6%; P = 0.038). In the SLE group, 6 of 7 antiphospholipid (aPL) antibody-positive versus 3 of 17 aPL antibody-negative patients experienced thrombotic events ( P = 0.015). Recurrence of lupus nephritis was documented in 3 renal grafts (8.6%), but no graft was lost because of recurrent lupus nephritis. CONCLUSION: Long-term patient and graft survival probabilities were similar in patients with SLE and matched controls. The risk for thrombotic complications was greater in patients with SLE, particularly aPL-positive patients. Nephritis recurred in less than 10% of patients with SLE and did not influence graft survival.
Assuntos
Transplante de Rim/estatística & dados numéricos , Nefrite Lúpica/cirurgia , Adulto , Anticorpos Antifosfolipídeos/sangue , Creatinina/sangue , Feminino , Seguimentos , Rejeição de Enxerto/tratamento farmacológico , Rejeição de Enxerto/epidemiologia , Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto , Hepatite C Crônica/complicações , Humanos , Hipertensão/epidemiologia , Imunossupressores/uso terapêutico , Infecções/epidemiologia , Itália/epidemiologia , Tábuas de Vida , Nefrite Lúpica/tratamento farmacológico , Nefrite Lúpica/imunologia , Nefrite Lúpica/mortalidade , Masculino , Complicações Pós-Operatórias/epidemiologia , Prognóstico , Recidiva , Risco , Trombofilia/sangue , Trombofilia/epidemiologia , Trombofilia/etiologia , Trombose/epidemiologia , Resultado do TratamentoRESUMO
The indications and the choice of renal replacement therapy for lupus patients are similar to those for other uremic patients. However, lupus patients can pose some particular problems. First, 10-28% of patients needing dialysis can have a partial renal function recovery. Therefore, the clinician has to decide whether to administer a rescue treatment, risking side-effects, or to reduce immunosuppression precluding a potential recovery. Many patients on regular dialysis show subdued biological and clinical activity. Others can show a hectic disease activity, particularly in the 1st year. In these cases, treatment is difficult, as vigorous immunosuppression can expose uremic patients to severe side-effects. The presence of circulating antiphospholipid antibodies (aPL) can favor thrombosis or stenosis of vascular access (VA). Renal transplantation is the best therapy for most lupus patients with end-stage renal failure. Many, but not all, studies have reported similar patient and graft survival rates in lupus and in non-lupus transplant recipients. The results are much better with living donor transplantation. Patients with aPL, black patients and those on long-term dialysis have a higher graft failure risk. Candidates with active lupus and/or those with significant iatrogenic morbidity should be advised to wait 6-12 months before transplantation. The recurrence risk of lupus nephritis ranged between 2% and 30% in different studies. The histological picture does not usually show severe features. Antiplatelet agents or anticoagulation can be advised for aPL patients.
Assuntos
Nefrite Lúpica/terapia , Terapia de Substituição Renal , Humanos , Imunossupressores/uso terapêutico , Transplante de Rim , Diálise Peritoneal/efeitos adversos , Diálise Renal/efeitos adversosRESUMO
Human Vgamma9/Vdelta2(+) T lymphocytes participate in the immune response against intracellular pathogens through the secretion of type-1 cytokines and chemokines and by killing of infected cells. Little is known of the effects by type-2 differentiation of gamma delta cells on these functions. Here, we report that bona fide naive cord blood-derived gamma delta lymphocytes expanded in vitro with the mycobacterial antigen isopentenyl pyrophosphate (IPP) can be differentiated as either type-1 or type-2 cells, in the presence of an appropriate cytokine milieu. Instead, peripheral gamma delta cells from PPD-negative healthy adults displayed a type-1 cytokine profile, i.e. IPP-stimulated secretion of IFN-gamma, but not of IL-4 and IL-10. Moreover, they released the macrophage inflammatory protein (MIP)-1beta, but not IL-8 nor the Th2 chemoattractants I-309 and TARC (thymus and activation-regulated chemokine). This cytokine profile was not significantly affected by in vitro culture in Th2 polarizing conditions. Only in one case out of seven were peripheral gamma delta cells fully differentiated to type-2 lymphocytes, characterized by sustained IL-4 and IL-10 production, along with secretion of substantial amounts of IL-8, I-309 and TARC. Type-2 gamma delta T lymphocytes preferentially expressed the co-stimulatory molecule CD30; conversely, no skewing in chemokine receptor expression was observed. Both polarized populations displayed high levels of CXCR3 in the absence of CCR3, CCR4 and CCR5. Finally, type-1, but not type-2, gamma delta T lymphocytes killed IPP-pulsed U937 cells and displayed elevated perforin content. Overall, our data suggest that type-2 differentiation of gamma delta T lymphocytes profoundly affects both their effector functions and their potential to recruit the appropriate leukocyte subsets to the sites of inflammation.
Assuntos
Quimiocinas/biossíntese , Citotoxicidade Imunológica , Hemiterpenos , Receptores de Antígenos de Linfócitos T gama-delta/análise , Receptores de Quimiocinas/análise , Células Th1/imunologia , Células Th2/imunologia , Diferenciação Celular , Humanos , Interferon gama/biossíntese , Interleucina-4/biossíntese , Antígeno Ki-1/análise , Glicoproteínas de Membrana/biossíntese , Compostos Organofosforados/imunologia , Perforina , Proteínas Citotóxicas Formadoras de Poros , Células U937RESUMO
Hypoglycaemia associated with lactic acidosis is a rare complication of lymphomas; only four cases have been previously reported. Recent studies provide evidence of direct consumption of glucose by the tumour cells, leading to lactic acidosis. We report the case of a 64-year-old patient with a gastric diffuse large B cell non-Hodgkin's lymphoma transformed from an indolent mucosa associated lymphoid tissue (MALT) lymphoma, admitted to our department for acute renal failure due to a tumour lysis syndrome. After recovery from renal failure, she developed severe hypoglycaemia and lactic acidosis refractory to therapy. She died after the onset of shock and coma.